Patents Assigned to Hancock Jaffe Laboratories
-
Patent number: 10959841Abstract: An implantable vein frame is contemplated in which two ring members are rigidly joined in spaced axial alignment via one or more interconnecting members. One of the one or more interconnecting members defines a protruding region that acts upon the implant placed within the frame and/or the vein that the vein frame is placed within to define a sinus region. The implant is placed within and scaffolded by the vein frame, and the vein frame is subsequently inserted within a vein via a venotomy, or interposed between two vein segments via vein interposition graft. The vein frame acts to support the structural integrity of the implant, and to scaffold and anchor the implant in place with the vein.Type: GrantFiled: November 14, 2017Date of Patent: March 30, 2021Assignee: Hancock Jaffe Laboratories, Inc.Inventors: Susan I. Montoya, Marc Glickman, Yury Zhivilo
-
Patent number: 10583218Abstract: An injectable composition having dermal filling and tissue expanding activity comprises: (1) a quantity of elastin sufficient to bring about dermal filling and tissue expansion when injected into a subject in need of dermal filling and tissue expansion; and (2) a pharmaceutically acceptable carrier. The composition can further comprise collagen; in other alternatives, the composition can further comprise hyaluronic acid; and one or more of the elastin, the collagen, and the hyaluronic acid, if present can be cross-linked, either intramolecularly or intermolecularly. The elastin, however, is the primary filler, even if collagen or hyaluronic acid are included in the composition.Type: GrantFiled: February 1, 2016Date of Patent: March 10, 2020Assignee: HANCOCK JAFFE LABORATORIES AESTHETICS, INC.Inventors: Bo Han, Marcel E. Nimni
-
Publication number: 20180133004Abstract: An implantable vein frame is contemplated in which two ring members are rigidly joined in spaced axial alignment via one or more interconnecting members. One of the one or more interconnecting members defines a protruding region that acts upon the implant placed within the frame and/or the vein that the vein frame is placed within to define a sinus region. The implant is placed within and scaffolded by the vein frame, and the vein frame is subsequently inserted within a vein via a venotomy, or interposed between two vein segments via vein interposition graft. The vein frame acts to support the structural integrity of the implant, and to scaffold and anchor the implant in place with the vein.Type: ApplicationFiled: November 14, 2017Publication date: May 17, 2018Applicant: HANCOCK JAFFE LABORATORIES, INC.Inventors: SUSAN I. MONTOYA, MARC GLICKMAN, YURY ZHIVILO
-
Publication number: 20180028723Abstract: A bioprosthetic valve for repairing a deep venous insufficiency in a subject includes a single leaflet from a xenogeneic heart valve attached at natural margins of attachment to a patch of valve wall tissue. The patch may extend axially above and below the leaflet and circumferentially on either side of the leaflet to provide a region for attaching the patch to a fenestration in a host vein. A bioprosthetic valve may be manufactured by excising a portion of a xenogeneic heart valve including a single leaflet and contiguous wall tissue, and may further comprise shaving off excess leaflet tissue from adjacent leaflets. A method of replacing a malfunctioning venous valve in a subject includes providing a bioprosthetic valve as described above and inserting it to the host vein.Type: ApplicationFiled: September 21, 2017Publication date: February 1, 2018Applicant: HANCOCK JAFFE LABORATORIES, INC.Inventor: NORMAN JAFFE
-
Patent number: 9248165Abstract: An injectable composition having dermal filling and tissue expanding activity comprises (1) a quantity of elastin sufficient to bring about dermal filling and tissue expansion when injected into a subject in need of dermal filling and tissue expansion, and (2) a pharmaceutically acceptable carrier. The composition can further comprise collagen, in other alternatives, the composition can further comprise hyaluronic acid, and one or more of the elastin, the collagen, and the hyaluronic acid, if present can be cross-linked, either intramolecularly or intermolecularly. The elastin, however, is the primary filler, even if collagen or hyaluronic acid are included in the composition.Type: GrantFiled: November 3, 2009Date of Patent: February 2, 2016Assignee: HANCOCK-JAFFE LABORATORIES, INC.Inventors: Bo Han, Marcel E. Nimni
-
Publication number: 20120010146Abstract: An injectable composition having dermal filling and tissue expanding activity comprises (1) a quantity of elastin sufficient to bring about dermal filling and tissue expansion when injected into a subject in need of dermal filling and tissue expansion, and (2) a pharmaceutically acceptable carrier. The composition can further comprise collagen, in other alternatives, the composition can further comprise hyaluronic acid, and one or more of the elastin, the collagen, and the hyaluronic acid, if present can be cross-linked, either intramolecularly or intermolecularly.Type: ApplicationFiled: November 3, 2009Publication date: January 12, 2012Applicant: HANCOCK JAFFE LABORATORIES, INC.Inventors: Bo Han, Marcel E. Nimni
-
Publication number: 20100234939Abstract: A bioprosthetic valve for repairing a deep venous insufficiency in a subject includes a single leaflet from a xenogeneic heart valve attached at natural margins of attachment to a patch of valve wall tissue. The patch may extend axially above and below the leaflet and circumferentially on either side of the leaflet to provide a region for attaching the patch to a fenestration in a host vein. A bioprosthetic valve may be manufactured by excising a portion of a xenogeneic heart valve including a single leaflet and contiguous wall tissue, and may further comprise shaving off excess leaflet tissue from adjacent leaflets. A method of replacing a malfunctioning venous valve in a subject includes providing a bioprosthetic valve as described above and inserting it to the host vein.Type: ApplicationFiled: May 27, 2010Publication date: September 16, 2010Applicant: Hancock Jaffe LaboratoriesInventor: Norman Jaffe
-
Publication number: 20090105810Abstract: A bioprosthetic valve for repairing a deep venous insufficiency in a subject includes a single leaflet from a xenogeneic heart valve attached at natural margins of attachment to a patch of valve wall tissue. The patch may extend axially above and below the leaflet and circumferentially on either side of the leaflet to provide a region for attaching the patch to a fenestration in a host vein. A bioprosthetic valve may be manufactured by excising a portion of a xenogeneic heart valve including a single leaflet and contiguous wall tissue, and may further comprise shaving off excess leaflet tissue from adjacent leaflets. A method of replacing a malfunctioning venous valve in a subject includes providing a bioprosthetic valve as described above and inserting it to the host vein.Type: ApplicationFiled: October 15, 2008Publication date: April 23, 2009Applicant: Hancock Jaffe LaboratoriesInventor: Norman Jaffe
-
Patent number: 5843181Abstract: Disclosed is a controlled autolysis method for making biological tissue substantially acellular by exposing the biological material, prior to any fixation thereof, to at least one buffered solution having a pH in the range from about 5.0 to 8.0 and a temperature in the range from about 12.degree. C. to 30.degree. C. for a sufficient period of time to render at least one region of the biological material substantially acellular while substantially preserving the structural integrity and non-cellular structural components of the biological material. Also disclosed is a method of making a bioprosthetic heart valve using biological material that has been treated by controlled autolysis and a method of treating a mammal having a defective heart valve using a bioprosthetic heart valve made, in part, by controlled autolysis.Type: GrantFiled: January 17, 1997Date of Patent: December 1, 1998Assignee: Hancock Jaffe LaboratoriesInventors: Norman Jaffe, Warren D. Hancock
-
Patent number: 5843180Abstract: Disclosed is a controlled autolysis method for making biological tissue substantially acellular by exposing the biological material, prior to any fixation thereof, to at least one buffered solution having a pH in the range from about 5.0 to 8.0 and a temperature in the range from about 12.degree. C. to 30.degree. C. for a sufficient period of time to render at least one region of the biological material substantially acellular while substantially preserving the structural integrity and non-cellular structural components of the biological material. Also disclosed is a method of making a bioprosthetic heart valve using biological material that has been treated by controlled autolysis and a method of treating a mammal having a defective heart valve using a bioprosthetic heart valve made, in part, by controlled autolysis.Type: GrantFiled: January 17, 1997Date of Patent: December 1, 1998Assignee: Hancock Jaffe LaboratoriesInventors: Norman Jaffe, Warren D. Hancock
-
Patent number: 5595571Abstract: Disclosed is a controlled autolysis method for making biological tissue substantially acellular by exposing the biological material, prior to any fixation thereof, to at least one buffered solution having a pH in the range from about 5.0 to 8.0 and a temperature in the range from about 12.degree. C. to 30.degree. C. for a sufficient period of time to render at least one region of the biological material substantially acellular while substantially preserving the structural integrity and non-cellular structural components of the biological material. Also disclosed is a method of making a bioprosthetic heart valve using biological material that has been treated by controlled autolysis and a method of treating a mammal having a defective heart valve using a bioprosthetic heart valve made, in part, by controlled autolysis.Type: GrantFiled: April 18, 1994Date of Patent: January 21, 1997Assignee: Hancock Jaffe LaboratoriesInventors: Norman Jaffe, Warren B. Hancock
-
Patent number: 4813958Abstract: Anisotropic mammalian diaphragm is crosslinked using, for example, glutaraldehyde and used as a surgical implant graft for repair of tissues which accommodate to relative movement of tendons, joints, etc.Type: GrantFiled: October 14, 1986Date of Patent: March 21, 1989Assignee: Hancock Jaffe LaboratoriesInventor: France T. Dixon
-
Patent number: 4813964Abstract: A xenogeneic tissue replacement for nonfunctional flexor tendon pulley comprising crosslinked, bovine or porcine or other anisotropic mammalian diaphragm and method of use are disclosed.Type: GrantFiled: October 14, 1986Date of Patent: March 21, 1989Assignee: Hancock Jaffe LaboratoriesInventors: France T. Dixon, Royce C. Lewis, Jr.
-
Patent number: 4798611Abstract: Xenogeneic tissue implants prepared by precrosslinking proteins in xenogeneic tissue using, for example, glutaraldehyde, and thereafter irradiating the crosslinked tissue with high energy radiation, e.g. gamma radiation, to sterilize, reduce the immunogenicity and improve the compliance and physical properties of the tissue are disclosed.Type: GrantFiled: October 14, 1986Date of Patent: January 17, 1989Assignee: Hancock Jaffe LaboratoriesInventor: Donald C. Freeman, Jr.